Display Settings:

Format

Send to:

Choose Destination
    Science. 1997 Jun 13;276(5319):1719-24.

    HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.

    Source

    Telethon Institute for Gene Therapy (TIGET), Istituto Scientifico H. S. Raffaele, 20132 Milan, Italy.

    Abstract

    In allogeneic bone marrow transplantation (allo-BMT), donor lymphocytes play a central therapeutic role in both graft-versus-leukemia (GvL) and immune reconstitution. However, their use is limited by the risk of severe graft-versus-host disease (GvHD). Eight patients who relapsed or developed Epstein-Barr virus-induced lymphoma after T cell-depleted BMT were then treated with donor lymphocytes transduced with the herpes simplex virus thymidine kinase (HSV-TK) suicide gene. The transduced lymphocytes survived for up to 12 months, resulting in antitumor activity in five patients. Three patients developed GvHD, which could be effectively controlled by ganciclovir-induced elimination of the transduced cells. These data show that genetic manipulation of donor lymphocytes may increase the efficacy and safety of allo-BMT and expand its application to a larger number of patients.

    PMID:
    9180086
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk